Current treatment status-Did not start treatment yet Posts on Medivizor
Navigation Menu

Current treatment status-Did not start treatment yet Posts on Medivizor

Using focal lesions seen on PET-CT to monitor outcome in multiple myeloma

Posted by on Jul 18, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study examined the use of PET-CT imaging to monitor response to treatment for multiple myeloma. The study concluded that treatment to suppress focal lesions seen on PET-CT is an important goal for newly diagnosed patients. Some background One way to improve outcomes in multiple myeloma is to customize treatment based on the...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Does radiotherapy improve outcomes for patients with primary breast diffuse large B-cell lymphoma?

Posted by on Jul 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of radiotherapy on the outcomes of rituximab (Rituxan)-treated patients with primary breast diffuse large B-cell lymphoma. This study concluded that radiotherapy has significant therapeutic benefits for these patients. Some background Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare type of...

Read More

Comparing obinutuzumab and rituximab in first-line chemotherapy regimens for follicular lymphoma

Posted by on Jul 2, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...

Read More

How accurate is PET/CT in identifying bone marrow involvement in children with Hodgkin lymphoma?

Posted by on Jun 28, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the accuracy of positron emission tomography/computed tomography (PET/CT) scanning and bone marrow biopsy (BMB) to assess bone marrow involvement (BMI) in children with newly diagnosed Hodgkin lymphoma. The main finding was that PET/CT was effective in determining BMI and biopsy should only be...

Read More

The effect of other conditions on ibrutinib treatment of CLL

Posted by on Jun 26, 2018 in Leukemia | 0 comments

In a nutshell The study looked at the impact of other medical conditions (comorbidities) on the effectiveness of ibrutinib (Imbruvica) in the treatment of chronic lymphocytic leukemia (CLL). The study concluded that having a number of other conditions was associated with a poorer prognosis in CLL patients treated with ibrutinib. Some background...

Read More

Does 8 cycles of R-CHOP lead to better survival than 6 cycles for diffuse large B-cell lymphoma?

Posted by on Jun 21, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined whether 6 or 8 cycles of R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy led to better survival outcomes in patients with newly diagnosed diffuse large B-cell lymphoma. This study concluded that outcomes following 6 or 8 cycles of R-CHOP-21 are similar for these patients. Some...

Read More

Does bendamustine treatment increase risk of infections in non-Hodgkin Lymphoma?

Posted by on Jun 21, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of infection in older patients with indolent non-Hodgkin lymphoma (nHL) treated with bendamustine (Treanda). Researchers concluded that nHL patients treated with bendamustine had increased risk of common bacterial, fungal, and viral infections. Some background Bendamustine is a chemotherapy drug sometimes...

Read More